5 research outputs found
Immunophenotypic characterization of acute myeloid leukemia in adults and its role in the diagnosis,monitoring, and prognosis of the disease
U tezi su ispitivani savremeni aspekti primene imunofenotipizacije
multiparametarskom protočnom citofluorimetrijom (IMPC) u dijagnostici i
praćenju AML. Ispitivanjem je obuhvaćeno 320 odraslih bolesnika sa de novo
AML, od kojih je 294 uključeno u retrospektivno ispitivanje (dijagnoza,
klasifikacija i prognoza), dok je ostalih 26 bolesnika bilo uključeno u
prospektivno ispitivanje (praćenje minimalne rezidualne bolesti - MRB).
Bolesnici su klasifikovani kao AML-neklasifikovana (48%), AML sa
rekurentnim genetskim poremećajima (37,4%) i AML sa znacima
mijelodisplazije (14,6%). IPCM omogućava postavljanje dg AML analizom ks
kod 98% bolesnika. Ispitivanjem 44 različita hLDM utvrđeno je da je njihova
ekspresija na blastima deregulisana, o čemu govore aberacije u njihovoj
ekspresiji kod svakog bolesnika. Heterogen ćelijski sastav populacije
leukemijskih ćelija (leukemijski blasti i prekursori) utvrđen je kod 55%
bolesnika sa AML. Imunološka i citomorfološka klasfikacija AML su saglasne
kod 73% bolesnika, odnosno imunološka i SZO klasifikacija kod 68%
bolesnika. Ispitivanje MRB sprovedeno je primenom jedne (42%) ili dve
(58%) kombinacije IFSL po bolesniku. Primenom IMPC, pokazana je visoka
učestalost MRB kod naših bolesnika sa AML posle lečenja indukcionom
(69%) odnosno konsolidacionom terapijom (50%). Nivo MRB u ks bolesnika
≥0,1% NĆ posle indukcione terapije, svrstava bolesnike u grupu visokog
rizika za razvoj relapsa bolesti. Ispitivanje prognostičkog značaja hLDM kod
bolesnika sa AML, pokazalo je značajnu vezu između rane monocitne
diferencijacije leukemijskih ćelija, ekspresije CD22 molekula i pojave rane
smrti i (p<0,05), odnosno niže incidence kompletne remisije (p<0,05)...In the thesis are examined modern aspects of application
immunophenotyping and multiparameter flow cytometry (IMPC) in the
diagnosis and monitoring of AML. The study included 320 adult patients
with de novo AML, of which 294 included in the retrospective study
(diagnosis, classification and prognosis), while the other 26 patients were
included in a prospective study (minimal residual disease - MRD). Patients
were classified as AML-unclassified (48%), AML with recurrent genetic
abnormalities (37.4%) and AML with signs of myelodysplasia (14.6%). IPCM
allows setting dg AML by analysis of bone marrow (bm) in 98% of patients.
By examining of 44 different HLDM, it was found that its expression is
deregulated on the blasts, whereas at least one type of immunophenotypic
aberrations was found per patient. Heterogeneous cellular composition of
the population of leukemic cells (leukemic blasts and precursors) was found
in 55% of patients with AML. Immunological and cytomorphological
classification of AML agree with 73% of patients, respectively immunological
and WHO classification in 68% of patients. MRD trial was conducted by one
(42%) or two (58%) combination of IFSL per patient. By applying the IMPC,
a high incidence of MRD was detected in our patients with AML, after
induction (69%) and/or consolidation therapy (50%). The level of MRD in
bm of patients ≥0,1% NC after induction therapy, classified patients in the
high risk group for the development of relapse. The prognostic significance
of HLDM in patients with AML, showed a significant association between
early monocytic differentiation of leukemia cells, the expression of CD22
molecule and the appearance of early death (p<0.05), and lower incidence of
complete remission (p<0.05)..
The emergence of non-secretory multiple myeloma during the non-cytotoxic treatment of essential thrombocythemia: A case report
Introduction. The emergence of multiple myeloma as a second malignancy in patients with essential thrombocythemia is extremely rare. Several cases have been published so far, pointing out the impact of a cytotoxic effect during treatment of essential thrombocythemia on the development of multiple myeloma. Case presentation. We report the case of a 52-year-old Caucasian man who presented to our hospital because of leukocytosis, a slightly decreased hemoglobin level and thrombocytosis. After a complete hematological work-up, essential thrombocythemia was diagnosed. The patient was included in a multicenter clinical study, treated with anagrelide and his platelet counts were maintained in the normal range for more than 3 years. A sudden drop in his hemoglobin level with normal leukocyte and platelet count occurred at the same time as a back pain. Magnetic resonance imaging of his spine revealed the existence of a pathological fracture of Th4, the collapse of the upper edge of Th7 and osteolytic lesions of multiple thoracic vertebrae. Repeated hematological examinations, including bone biopsy with immunohistochemistry, disclosed diagnosis of multiple myeloma of the non-secretory type. Conclusions: To the best of our knowledge this is the first published case in which multiple myeloma developed during the treatment of essential thrombocythemia with the non-cytotoxic drug anagrelide. Our attempts to find a common origin for the coexistence of multiple myeloma and essential thrombocythemia have not confirmed the genetic basis of their appearance. Further studies are needed to determine the biological impact of this coexistence
Immunophenotypic characterization of acute myeloid leukemia in adults and its role in the diagnosis,monitoring, and prognosis of the disease
U tezi su ispitivani savremeni aspekti primene imunofenotipizacije
multiparametarskom protočnom citofluorimetrijom (IMPC) u dijagnostici i
praćenju AML. Ispitivanjem je obuhvaćeno 320 odraslih bolesnika sa de novo
AML, od kojih je 294 uključeno u retrospektivno ispitivanje (dijagnoza,
klasifikacija i prognoza), dok je ostalih 26 bolesnika bilo uključeno u
prospektivno ispitivanje (praćenje minimalne rezidualne bolesti - MRB).
Bolesnici su klasifikovani kao AML-neklasifikovana (48%), AML sa
rekurentnim genetskim poremećajima (37,4%) i AML sa znacima
mijelodisplazije (14,6%). IPCM omogućava postavljanje dg AML analizom ks
kod 98% bolesnika. Ispitivanjem 44 različita hLDM utvrđeno je da je njihova
ekspresija na blastima deregulisana, o čemu govore aberacije u njihovoj
ekspresiji kod svakog bolesnika. Heterogen ćelijski sastav populacije
leukemijskih ćelija (leukemijski blasti i prekursori) utvrđen je kod 55%
bolesnika sa AML. Imunološka i citomorfološka klasfikacija AML su saglasne
kod 73% bolesnika, odnosno imunološka i SZO klasifikacija kod 68%
bolesnika. Ispitivanje MRB sprovedeno je primenom jedne (42%) ili dve
(58%) kombinacije IFSL po bolesniku. Primenom IMPC, pokazana je visoka
učestalost MRB kod naših bolesnika sa AML posle lečenja indukcionom
(69%) odnosno konsolidacionom terapijom (50%). Nivo MRB u ks bolesnika
≥0,1% NĆ posle indukcione terapije, svrstava bolesnike u grupu visokog
rizika za razvoj relapsa bolesti. Ispitivanje prognostičkog značaja hLDM kod
bolesnika sa AML, pokazalo je značajnu vezu između rane monocitne
diferencijacije leukemijskih ćelija, ekspresije CD22 molekula i pojave rane
smrti i (p<0,05), odnosno niže incidence kompletne remisije (p<0,05)...In the thesis are examined modern aspects of application
immunophenotyping and multiparameter flow cytometry (IMPC) in the
diagnosis and monitoring of AML. The study included 320 adult patients
with de novo AML, of which 294 included in the retrospective study
(diagnosis, classification and prognosis), while the other 26 patients were
included in a prospective study (minimal residual disease - MRD). Patients
were classified as AML-unclassified (48%), AML with recurrent genetic
abnormalities (37.4%) and AML with signs of myelodysplasia (14.6%). IPCM
allows setting dg AML by analysis of bone marrow (bm) in 98% of patients.
By examining of 44 different HLDM, it was found that its expression is
deregulated on the blasts, whereas at least one type of immunophenotypic
aberrations was found per patient. Heterogeneous cellular composition of
the population of leukemic cells (leukemic blasts and precursors) was found
in 55% of patients with AML. Immunological and cytomorphological
classification of AML agree with 73% of patients, respectively immunological
and WHO classification in 68% of patients. MRD trial was conducted by one
(42%) or two (58%) combination of IFSL per patient. By applying the IMPC,
a high incidence of MRD was detected in our patients with AML, after
induction (69%) and/or consolidation therapy (50%). The level of MRD in
bm of patients ≥0,1% NC after induction therapy, classified patients in the
high risk group for the development of relapse. The prognostic significance
of HLDM in patients with AML, showed a significant association between
early monocytic differentiation of leukemia cells, the expression of CD22
molecule and the appearance of early death (p<0.05), and lower incidence of
complete remission (p<0.05)..